Changing gears …. there is much debate out there with respect to the risk of genetic drift and genetic bottlenecking … capsule delivery allows to a degree for pinpoint dosing and formulations. Is such a delivery (and the extraction process) somewhat of a hedge against these risk factors?
It’s not a hedge, it’s a complete solution. We can extract the constituents for our products from many sources including hemp, cannabis trim, seeds and so forth. Basically, any part of the plant. Once we have the extracts, we are able to isolate the cannabinoids that we’d like to use for various formulations. As a result, we aren’t concerned about genetic drift because we are working with the specific molecules in specific amounts, regardless of their origin.
To be clear, cannabinoids don’t have to come from cannabis. Take into consideration that our partner, FSD Pharma, recently arranged a research agreement with Solarvest to develop algae-based, pharma-grade cannabinoids.
Canada pursuant to the Cannabis Act and Cannabis Regulations, we are very close to being in a position to sell our products and generate revenue. The FSD license allows us to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable us to launch production and sales out of our manufacturing facility located in Room 6 of FSD’s Health Canada approved facility in Cobourg, Ontario. In addition, the FSD license, when combined with an export permit, which FSD intends to acquire as soon as possible, may also allow us to sell its products in foreign markets, including Australia and Mexico where we have already cultivated partnerships.
For the first time in our companies three year history, we have a path to revenue, from extracts, through manufacturing and finally to sales. That’s what makes us an exciting prospect, we have the technology, we have the management team that has been here before, and now we finally have the means to generate revenue. As a result, we are expecting the last half of 2019 to be all about revenue, revenue revenue.
162